KPTIKaryopharm Therapeutics IncRunning, no new patients
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma
1Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.3
6 insiders sold shares within a month
Since May 14, 2026 · was worth 10, fading over time
Worry score1
Score over time
- Stage
- Phase 2
- Patients
- 244 (planned)
- Started
- Nov 2014
- Main results expected
- Dec 2026
- Fully finished
- Dec 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Overall Response Rate (ORR)
Measured over: One year
Part 2: Overall Response Rate (ORR) Based on Lugano Criteria
Measured over: From initial randomization until date of disease progression or death (maximum of 1 year from Part 2 randomization)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.3, since 2026-05-14, fades (half-life)
Raw record changes
- none yet
Trial ID NCT02227251 · record last updated 2026-10-01 · checked 2026-11-09 15:47 UTC